Send to

Choose Destination

See 1 citation found by title matching your search:

Oncoimmunology. 2015 Mar 19;4(6):e1008354. eCollection 2015 Jun.

T cell receptor-therapy in HBV-related hepatocellularcarcinoma.

Author information

Program Emerging infectious Diseases; Duke-NUS Medical School ; Singapore, Singapore ; Singapore Institute for Clinical Sciences; ASTAR ; Singapore, Singapore ; School of Immunity and Infection; College of Medical and Dental Science; University of Birmingham ; Edgbaston, Birmingham, UK.
Hepatology Unit; University Hospital of Pisa ; Pisa, Italy.
Division of Infection & Immunity; Institute of Immunity & Transplantation; University College London ; London, UK.
General Medicine; Liver and Digestive Disease Unit; University Hospital of Pisa ; Pisa, Italy.
Institute of Child Health & Great Ormond Street Hospital; University College London ; London, UK.


Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific antigen and thus be targeted by adoptively transferred HBV-specific TCR redirected T cells.


CHB, Chronic hepatitis B; HBV; SCID, Severe combined immunodeficiency; T cell therapy; hepatocellularcarcinoma

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center